Haloperidol for Gastroparesis: Dosing and ECG Monitoring

Dosing and Alternatives

The American Gastroenterological Association recommends trying 5-HT3 antagonists, such as ondansetron 4-8 mg BID-TID or granisetron 1 mg BID, as an alternative to haloperidol for gastroparesis treatment 1
The American Gastroenterological Association suggests using phenothiazines, such as prochlorperazine 5-10 mg QID or chlorpromazine 10-25 mg TID-QID, as another alternative to haloperidol for gastroparesis treatment 1
The American Gastroenterological Association recommends considering NK-1 antagonists, such as aprepitant 80 mg/day, as an alternative to haloperidol for gastroparesis treatment 1
The American Gastroenterological Association suggests using prokinetics, such as metoclopramide or domperidone, as an alternative to haloperidol for gastroparesis treatment 3

The American Gastroenterological Association guidelines warn about QT prolongation and ventricular tachycardia risks with dopamine antagonists used in gastroparesis, and recommend obtaining a baseline ECG to assess QTc interval before administering haloperidol 2, 3
A baseline ECG should be obtained to assess QTc interval, with normal values being <450 ms in men and <460 ms in women, before administering haloperidol 3
Electrolyte abnormalities, such as hypokalemia and hypomagnesemia, should be corrected before administration of haloperidol, as they potentiate QT prolongation risk 3

The American Gastroenterological Association guidelines recommend screening for contraindications to haloperidol, including prolonged baseline QTc (>500 ms), concurrent QT-prolonging medications, severe electrolyte disturbances, history of torsades de pointes, and Parkinson's disease 1, 3
The American Gastroenterological Association guidelines recommend monitoring for extrapyramidal symptoms, such as akathisia and dystonia, which can occur acutely with haloperidol use 1